Jump to any asset
849 assets, updated daily
As of September 27, 2026, Pfizer Inc. (PFE) trades at $28.67. CleaRank Financial AI rates it Hold with a fair value of $28.67, in line with the current price. Wall Street's consensus target is $28.00 across 28 analysts. RSI at 55 is in neutral territory, and the price is above its 50-day average of $26.98.
Pfizer Inc. (PFE)
Pfizer Inc. NYSE
$28.67
0.2600 (0.92%)
At close: Sep 25, 4:00 PM EDT
AI Analyst Consensus
58 / 100
Pfizer Inc. (PFE) is currently trading at $28.67, positioned above its 50-day and 200-day moving averages ($26.98 and $26.34), suggesting a neutral to slightly positive short-term trend. The company's valuation, with a P/E ratio of 37.72, is above the healthcare sector median of 31.9, while its price-to-sales ratio of 2.57 is below the sector average of 3.7. Recent analyst ratings show a consensus 'Hold' with a median price target of $28.00, implying a slight downside from the current price. Insider activity indicates a 'Moderate Buy Signal' with net selling of $125.4M million versus $134.7 thousand in sales, primarily driven by CEO an insider's purchases. The company's financial health shows a return on equity of 5.01% and a profit margin of 6.80%, which are below the sector medians. However, its operating margin stands at a strong 27.88%. The debt-to-equity ratio of 0.74 is in line with the sector average. Despite a slight revenue contraction projected for the current and next quarters, forward revenue growth estimates for the next five years are negative at -4.4%, suggesting potential headwinds. The stock's dividend yield is approximately 6.00%.
PFE Price Analysis
Market Metrics
Open
$28.45
Day Range
$28.17 to $28.69
Prev Close
$28.41
Volume
27.76M
52-Week Range
$23.58 to $29.21
Market Cap
$163.41B
Peer Benchmarking
Valuation vs Sector (Healthcare)
Performance vs XLV
Sector Position Analysis
Valuation is broadly in line with sector peers (18% difference), suggesting fair market pricing relative to industry standards.
PFE Financial Performance
Revenue vs. Earnings
Annual
Quarterly
PFE Analysis
Company's Health
4/5
12-Month Analyst Target
-2.34% Downside
Median of 28 analysts (12-month)
$28.00
AI Technical Analysis
Pfizer Inc. (PFE) exhibits neutral momentum with an RSI of 54.7, trading above its 50-day and 200-day moving averages ($26.98 and $26.34), indicating that these moving averages are acting as support. The MACD is slightly positive at 0.28, suggesting a lack of strong directional conviction. The stochastic indicator is in overbought territory at 88.75, which could signal a potential short-term pullback. Volume has been below its average recently, with the latest volume at 27.76 million compared to an average of 35.14 million, a decrease of 21%. The current price of $28.67 is above its 50-day and 200-day moving averages ($26.98 and $26.34). The CCI at 188.51 suggests strong positive momentum, though this is tempered by the neutral RSI and overbought stochastic reading.
ProTips
- Monitor Pfizer's upcoming earnings reports closely for any signs of revenue stabilization or growth acceleration, as current projections indicate a decline.
- Given the neutral RSI and overbought stochastic reading, consider potential short-term volatility or a minor pullback in PFE's stock price.
- As an MLP, Pfizer Inc. issues Schedule K-1 tax forms instead of standard 1099-DIV forms, which may create complex tax obligations-especially if held in a retirement account (IRA/401k). Consult a tax advisor.
Key Catalysts
Bullish
Insider Buying Signals Moderate Accumulation
Insiders, including CEO an insider, have made net purchases totaling $3 million, indicating confidence in the company's future prospects.
Source: Insider Trading DataBearish
Projected Revenue and EPS Decline
Current estimates show a decline in revenue and EPS for the upcoming quarters and full year, alongside negative long-term growth projections.
Source: Analyst EstimatesNeutral
Median Analyst Price Target Suggests Limited Upside
The median analyst price target of $28.00 is slightly below the current stock price of $28.67, indicating a lack of significant upside potential.
Source: Wall Street SummaryNeutral
Overbought Stochastic Indicator
The stochastic indicator is at 88.75, suggesting the stock may be overbought in the short term and could experience a pullback.
Source: Technical AnalysisMarket Outlook
Pfizer Inc. (PFE) faces a challenging outlook, with projected revenue and EPS declines in the near term and negative growth estimates for the next five years. The current trading price of $28.67 is slightly above the median analyst price target of $28.00, suggesting limited upside potential. The company's valuation metrics, particularly its P/E ratio, appear rich relative to its growth prospects and current profitability. Key factors that could influence the stock's trajectory include the success of its drug pipeline and the market's reaction to upcoming earnings reports. While insider buying provides some support, the overall analyst sentiment leans towards 'Hold', reflecting concerns about future growth and current valuation. Investors should monitor the company's ability to reverse its revenue decline and achieve positive growth in the coming years.
Key Statistics
| Market Cap | 163.41B |
|---|---|
| P/E Ratio | 37.72 |
| EPS (TTM) | 0.7600 |
| Dividend Yield | 6.00% |
| 52 Week High | 29.21 |
| 52 Week Low | 23.58 |
Pfizer Inc. (PFE) trades at a P/E ratio of 37.72, which is higher than the healthcare sector median of 31.9, suggesting a premium valuation relative to its earnings. Its price-to-sales ratio of 2.57 is below the sector average of 3.7, indicating that the market values its revenue less than its peers. The company's return on equity is 5.01%, and its profit margin is 6.80%, both of which are below the sector medians of 6.9% and 8.1% respectively. Despite lower profitability metrics compared to sector averages, Pfizer maintains a strong operating margin of 27.88%. Its debt-to-equity ratio stands at 0.74, which is slightly above the sector median of 0.74, indicating a moderate level of leverage. The company's revenue growth is projected to be negative for the current and next quarters, and the consensus estimate for the next five years is a compound annual growth rate of -4.4%, signaling potential challenges in expanding its top line.
Earnings & Growth Analysis
Pfizer Inc. (PFE) is expected to report earnings per share of $0.75885 for the current quarter ending September 30, 2026, a decrease from $0.87 in the year-ago period, with an estimated sales growth of -4.00%. For the full year 2026, EPS is projected at $2.97497, down from $3.22 last year, and revenue is expected to decline by 1.00%. The company's growth estimates indicate a challenging near-term outlook, with projected EPS declines in the current and next quarters, and negative revenue growth expected for the next year.
Key Risks
Pfizer Inc. (PFE) faces risks related to its valuation, trading at a higher P/E ratio than the healthcare sector median, despite projected revenue and EPS declines. The company's forward growth estimates are negative, particularly for the next five years, suggesting potential long-term challenges in expanding its business. Also, the median analyst price target of $28.00 is slightly below the current trading price of $28.67, indicating limited upside potential according to Wall Street.
Technical Indicators
| RSI (14) | 54.70 |
|---|---|
| MACD | 0.28 |
| SMA 50 | 26.98 |
| SMA 200 | 26.34 |
RSI
Neutral
SMA Cross
Bullish
Price vs SMA
Bullish
MACD
Bullish
Golden Cross in effect with the 50-day SMA ($26.98) above the 200-day SMA ($26.34), price action is firmly bullish above key moving averages.
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
S&P 500 (SPY)
+0.26
Weak correlation
Nasdaq 100 (QQQ)
+0.14
Weak correlation
Bitcoin (BTC)
+0.09
Weak correlation
Gold (XAU)
+0.07
Weak correlation
Check Custom Correlation
How does any other asset move with PFE? One year of daily closes, Pearson correlation.
Try
PFE Trade Plans
Specific entry, exit, and risk management levels
Select Your Trade Bias
Risk Tolerance
Conservative
2%
Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →
Entry Strategies pick an entry style
Conservative
$28.38
Slight discount to current
Wait for small dip
Aggressive
$28.67
At current price
Enter now if confident
Risk Management
STOP LOSS
$27.53
MAX LOSS
-3.0%
Volatility-Adjusted Stop Loss
Calculated based on RSI (54.7) and current market volatility
Profit Targets (Based on Conservative Entry)
TARGET 1
$29.23
+3% (Conservative)
+2.0% (Aggressive)
TARGET 2
$29.80
+5% (Conservative)
+4.0% (Aggressive)
TARGET 3
$30.65
+8% (Conservative)
+6.9% (Aggressive)
Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3
Calculate Your Trade
Disclaimer
This AI-generated trade plan for PFE is for educational and informational purposes only and does not constitute financial advice. The analysis is based on historical data patterns and technical indicators which may not predict future results. Stock trading involves risk of loss. Verify all data independently and consult a qualified financial advisor. Generated on September 27, 2026.Growth of $10,000
A $10,000 investment in PFE in September 2016 would be worth about $8,932 today, compared with about $35,782 for the same investment in the S&P 500 benchmark.
Compare with Another Ticker
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in PFE today could grow to about $12,815 by 2036 in the base case, with a bull case near $34,127 and a bear case around $4,812. Projections are statistical simulations, not guarantees.
PFE Stock Price Prediction: 2030
CleaRank's simulation projects a price near $31.66 for PFE by 2030 in the base case, from $28.67 today (1.1x over 4 years). The downside path ends near $17.04. These are outcomes of a Monte Carlo simulation run on PFE's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | Downside (10th pct) | Base case | Upside (90th pct) |
|---|---|---|---|
| 2027 | $21.56 | $29.39 | $40.06 |
| 2028 | $19.44 | $30.13 | $46.69 |
| 2029 | $18.06 | $30.88 | $52.81 |
| 2030 | $17.04 | $31.66 | $58.82 |
| 2031 | $16.24 | $32.46 | $64.88 |
| 2032 | $15.58 | $33.27 | $71.05 |
| 2033 | $15.03 | $34.11 | $77.40 |
| 2034 | $14.56 | $34.96 | $83.96 |
| 2035 | $14.15 | $35.84 | $90.77 |
| 2036 | $13.80 | $36.74 | $97.84 |
Method: 10,000 simulated price paths using PFE's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice.
People Also Watch
PFE Insider Trading Analysis
Bought
$3.0M
3 Transactions
Sold
$134.7K
2 Transactions
Insiders
9
Active Traders
Avg Transaction
$619.0K
Moderate size
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Mar 4, 2019 | READ IAN C
Officer and Director
|
Sell | 530.1K | $22.9M |
| Jul 16, 2018 | READ IAN C
Chief Executive Officer
|
Sell | 486.8K | $18.2M |
| Nov 11, 2021 | YOUNG JOHN D
Officer
|
Sell | 150.0K | $7.5M |
| Jul 2, 2019 | D AMELIO FRANK A
Officer
|
Sell | 153.2K | $6.8M |
| Mar 4, 2019 | DOLSTEN MIKAEL G M.D., PH.D.
Officer
|
Sell | 149.6K | $6.5M |
| Aug 1, 2018 | D AMELIO FRANK A
Officer
|
Sell | 150.5K | $6.0M |
| Nov 9, 2020 | BOURLA ALBERT
Chief Executive Officer
|
Sell | 132.5K | $5.6M |
| May 1, 2018 | READ IAN C
Chief Executive Officer
|
Sell | 132.3K | $4.8M |
| May 18, 2020 | DOLSTEN MIKAEL G M.D., PH.D.
Officer
|
Sell | 95.4K | $3.6M |
| Nov 11, 2021 | DOLSTEN MIKAEL G M.D., PH.D.
Officer
|
Sell | 59.7K | $3.0M |
Page 1 of 1
Frequently Asked Questions
What is Pfizer Inc.'s current stock price and consensus rating?
Pfizer Inc. (PFE) is currently trading at $28.67. The consensus rating among Wall Street analysts is 'Hold', with a consensus score of 58 out of 100.
What is the median analyst price target for PFE stock?
The median analyst price target for Pfizer Inc. (PFE) is $28.00, which suggests a slight downside of -2.3% from its current trading price of $28.67.
How does Pfizer's valuation compare to the healthcare sector?
Pfizer Inc. (PFE) trades at a P/E ratio of 37.72, which is higher than the healthcare sector median of 31.9. However, its price-to-sales ratio of 2.57 is below the sector average of 3.7.
What is the recent insider trading activity for Pfizer Inc.?
Insider activity for Pfizer Inc. (PFE) indicates a 'Moderate Buy Signal', with insiders being net buyers. Total purchases amount to $3 million, primarily from CEO Albert Bourla, against $134.7 thousand in sales in recent filings.
What are the projected earnings and revenue growth estimates for Pfizer?
For the current year, Pfizer Inc. (PFE) is projected to have EPS of $2.97 and revenue of $62.2 billion, representing a year-over-year decline. Growth estimates are negative for the next five years at -4.4% annually.
Is Pfizer Inc. stock technically overbought or oversold?
Pfizer Inc. (PFE) shows neutral momentum with an RSI at 54.7. While the stochastic indicator is in overbought territory at 88.75, suggesting a potential short-term pullback, the stock is trading above its key moving averages, indicating support.
What is Pfizer's long-range projection for 2030?
Based on Monte Carlo simulations, Pfizer Inc. (PFE) has a base case projection of $31.66 for 2030, with a downside scenario of $17.04 and an upside scenario of $58.82. These are statistical outcomes, not guarantees.